Q-omics provides the consensus-scored UBA7 profile across patient tissues and cancer cell-line models. UBA7 expression is associated with patient survival in 28 of 34 cancer types, with the highest sampling consensus in SKCM. Among the 18 cancer types available for tumor–normal comparison, UBA7 is differentially expressed in 12, with the highest sampling consensus in LUAD. Additionally, UBA7 protein abundance shows 24,187 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight SKCM, LUAD, and LSCC as cancer lineages where UBA7 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for UBA7 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes UBA7 survival associations across molecular data types. UBA7 RNA expression shows survival associations in the most cancer types (28), followed by mutation status (7) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible UBA7 RNA expression–survival associations across cancer types. High UBA7 expression shows unfavorable associations in LGG and KIRC, but favorable associations in SKCM, BLCA, BRCA and HNSC. The SKCM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify SKCM as the clearest survival context for UBA7 RNA expression.
This table summarizes UBA7 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 5. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for UBA7. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. UBA7 shows lower tumor expression in LUAD, LUSC, UCEC, KICH and BRCA and higher tumor expression in KIRC. The LUAD box plot shows higher UBA7 RNA expression in normal versus tumor tissue (log2 FC = −0.969, t-test p < 0.001).
This table shows molecular features associated with UBA7 in patient tissues and cancer cell lines. In patient samples, UBA7 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, UBA7 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in OESOPHAGUS and CNS.
